Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-CMD: Efficacy of Diltiazem in Coronary Microvascular Dysfunction
NCT04777045Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of diltiazem in Coronary Microvascular Dysfunction (CMD), sponsored by Radboud University Medical Center. Started Oct 2019; status: active, not recruiting.
02
Drugs
diltiazem
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT04777045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777045.